Abstract

BackgroundHepatocyte-like cells (HLCs) derived from human induced pluripotent stem cells (iPSCs) hold great promise in toxicological applications as well as in regenerative medicine. Previous efforts on hepatocyte differentiation have mostly relied on the use of growth factors (GFs) to recapitulate developmental signals under in vitro conditions. Recently, the use of small molecules (SMs) has emerged as an attractive tool to induce cell fate transition due to its superiority in terms of both quality and cost. However, HLCs derived using SMs have not been well characterized, especially on the transcriptome level.MethodsHLCs were differentiated from human iPSCs using a protocol that only involves SMs and characterized by transcriptomic analysis using whole genome microarrays.ResultsHLCs derived using the SM protocol (HLC_SM) displayed specific hepatic marker expression and demonstrated key hepatic functions. Transcriptomic analysis of the SM-driven differentiation defined a hepatocyte differentiation track and characterized the expression of some key marker genes in major stages of hepatocyte differentiation. In addition, HLC_SM were scored with CellNet, a bioinformatics tool quantifying how closely engineered cell populations resemble their target cell type, and compared to primary human hepatocytes (PHHs), adult liver tissue, fetal liver tissue, HLCs differentiated using GFs (HLC_GF), and commercially available HLCs. Similar to HLC_GF, HLC_SM displayed a mixed phenotype of fetal and adult hepatocytes and had relatively low expression of metabolic enzymes, transporters, and nuclear receptors compared to PHHs. Finally, the differentially expressed genes in HLC_SM compared to HLC_GF and to PHHs were analyzed to identify pathways and upstream transcription regulators which could potentially be manipulated to improve the differentiation of HLCs.ConclusionsOverall, the present study demonstrated the usefulness of the SM-based hepatocyte differentiation method, offered new insights into the molecular basis of hepatogenesis and associated gene regulation, and suggested ways for further improvements in hepatocyte differentiation in order to obtain more mature HLCs that could be used in toxicological studies.

Highlights

  • Hepatocyte-like cells (HLCs) derived from human induced pluripotent stem cells hold great promise in toxicological applications as well as in regenerative medicine

  • Overall, the present study demonstrated the usefulness of the Small molecule (SM)-based hepatocyte differentiation method, offered new insights into the molecular basis of hepatogenesis and associated gene regulation, and suggested ways for further improvements in hepatocyte differentiation in order to obtain more mature HLCs that could be used in toxicological studies

  • Differentiation of Induced pluripotent stem cell (iPSC) to HLCs driven by SMs HLCs were differentiated from iPSCs using a protocol that only involves SMs [12]

Read more

Summary

Introduction

Hepatocyte-like cells (HLCs) derived from human induced pluripotent stem cells (iPSCs) hold great promise in toxicological applications as well as in regenerative medicine. There has been burgeoning interest in hepatocyte-like cells (HLCs) derived from human induced pluripotent stem cells (iPSCs) In addition to their therapeutic value in regenerative medicine such as hepatocyte transplantation for intractable liver diseases [1], these cells hold great promise in disease modeling, mechanistic study, drug development, and toxicological applications [2,3,4]. Previous efforts on hepatocyte differentiation have mostly relied on the use of growth factors (GFs) to recapitulate developmental signals under in vitro conditions, such as activin A, bone morphogenetic protein 4 (BMP4), fibroblast growth factor 2 (FGF2), hepatocyte growth factor (HGF), and oncostatin M [9] Cells generated using such protocols showed encouraging results in terms of marker expression and functional assays, but in all cases displayed an immature hepatic phenotype that more closely resembles fetal rather than adult hepatocytes [10]. The use of GFs in these protocols has the disadvantages of high cost, low reproducibility, and potential safety concerns for clinical applications

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.